OptimizeRx Corporation
OPRX
$16.99
-$0.26-1.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.90% | 20.66% | 28.81% | 40.40% | 35.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.90% | 20.66% | 28.81% | 40.40% | 35.15% |
| Cost of Revenue | 17.84% | 10.84% | 14.42% | 30.40% | 29.58% |
| Gross Profit | 30.84% | 26.95% | 38.41% | 47.14% | 38.82% |
| SG&A Expenses | 2.48% | 6.48% | 14.06% | 12.63% | 12.08% |
| Depreciation & Amortization | 20.56% | 44.91% | 80.15% | 128.99% | 90.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.39% | 9.26% | 16.06% | 21.04% | 19.45% |
| Operating Income | 136.06% | 70.47% | 52.96% | 53.44% | 39.01% |
| Income Before Tax | 64.56% | 36.28% | 22.87% | -143.00% | -83.37% |
| Income Tax Expenses | 106.77% | 90.25% | 109.58% | -27,854.55% | -25,378.79% |
| Earnings from Continuing Operations | 44.91% | 14.71% | -14.48% | -75.81% | -24.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.91% | 14.71% | -14.48% | -75.81% | -24.82% |
| EBIT | 136.06% | 70.47% | 52.96% | 53.44% | 39.01% |
| EBITDA | 220.99% | 112.43% | 82.54% | 75.16% | 55.31% |
| EPS Basic | 46.40% | 18.36% | -7.51% | -64.13% | -20.87% |
| Normalized Basic EPS | 86.46% | 32.41% | 7.91% | 14.11% | 11.62% |
| EPS Diluted | 46.28% | 18.67% | -6.97% | -65.46% | -21.91% |
| Normalized Diluted EPS | 86.13% | 32.41% | 7.91% | 14.11% | 11.62% |
| Average Basic Shares Outstanding | 4.07% | 5.60% | 6.82% | 6.85% | 2.34% |
| Average Diluted Shares Outstanding | 4.78% | 5.60% | 6.82% | 6.85% | 2.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |